title: Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.
abstract: Saccharomyces cerevisiae is widely used as a probiotic compound. Clinical data suggest that this agent is safe and effective. We report two cases of fungemia caused by S. cerevisiae occurring in immunosuppressed patients treated orally with S. boulardii Molecular typing confirmed clonality in isolate strains from patients and the capsule. Physicians caring for immunosuppressed patients must be aware of this potential serious complication of probiotic use.
authors.affiliation: Department of Internal Medicine, Universidad Católica de Chile, School of Medicine, Santiago, Chile.
authors.forename: Arnoldo J
authors.initials: AJ
authors.lastname: Riquelme
authors.forename: Mario A
authors.initials: MA
authors.lastname: Calvo
authors.forename: Ana M
authors.initials: AM
authors.lastname: Guzmán
authors.forename: María S
authors.initials: MS
authors.lastname: Depix
authors.forename: Patricia
authors.initials: P
authors.lastname: García
authors.forename: Carlos
authors.initials: C
authors.lastname: Pérez
authors.forename: Marco
authors.initials: M
authors.lastname: Arrese
authors.forename: Jaime A
authors.initials: JA
authors.lastname: Labarca
mesh_terms: D000328:Adult; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D016469:Fungemia / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D019936:Probiotics / Q000009:adverse effects* / Q000627:therapeutic use; D012440:Saccharomyces; D012441:Saccharomyces cerevisiae